Company profile for BlueRock Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BlueRock is using its unique cell+gene platform to direct cellular differentiation and genetically engineer cells to create an entirely new generation of cellular medicines in the areas of neurology, cardiology, and immunology. The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel...
BlueRock is using its unique cell+gene platform to direct cellular differentiation and genetically engineer cells to create an entirely new generation of cellular medicines in the areas of neurology, cardiology, and immunology. The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Founded in 2016 to capitalize on these technological breakthroughs, we are advancing our novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies across three therapeutic areas: neurology, cardiology, and immunology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, Massachusetts
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251006770906/en/BlueRock-Therapeutics-reports-positive-36-month-results-from-Phase-I-trial-of-bemdaneprocel-for-treating-Parkinsons-disease

BUSINESSWIRE
07 Oct 2025

https://www.fiercebiotech.com/biotech/bayer-owned-bluerock-lays-50-employees-shuts-cambridge-research-labs

FIERCE BIOTECH
26 Jun 2025

https://www.fiercebiotech.com/sponsored/forging-future-cell-therapy-bayer-and-bluerocks-unique-journey

FIERCE BIOTECH
02 Jun 2025

https://www.businesswire.com/news/home/20240927256345/en

BUSINESSWIRE
27 Sep 2024

https://www.indianpharmapost.com/drug-approval/bluerock-therapeutics-receives-fda-rmat-designation-for-parkinsons-disease-cell-therapy-candidate-bemdaneprocel-15706

INDINPHARMAPOST
31 May 2024

https://www.bayer.com/media/en-us/bluerock-therapeutics-phase-i-clinical-trial-for-parkinsons-disease-continues-to-show-positive-trends-at-18-months/

PRESS RELEASE
06 Mar 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty